{"url_path":"/sec/drio/8-k/2026-07-22/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-22","source_url":"https://www.sec.gov/Archives/edgar/data/1533998/0001104659-26-085900-index.html","accession_number":"0001104659-26-085900","cik":"0001533998","ticker":"DRIO","issuer_name":"DarioHealth Corp.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1533998/0001104659-26-085900-index.html","primary_entity_key":"0001533998","primary_entity_name":"DarioHealth Corp."},"word_count":116,"has_tables":true,"body_markdown":"**Item 9.01**\n**Financial Statements and Exhibits.**\n\n** **\n\n(d) Exhibits\n\n** **\n\n[4.1](tm2621105d1_ex4-1.htm)\n[Form of Pre-Funded Warrant](tm2621105d1_ex4-1.htm)\n\n \n \n\n[5.1](tm2621105d1_ex5-1.htm)\n[Opinion of Sullivan & Worcester LLP](tm2621105d1_ex5-1.htm)\n\n \n \n\n[10.1](tm2621105d1_ex10-1.htm)\n[Form of Securities Purchase Agreement](tm2621105d1_ex10-1.htm)\n\n \n \n\n[10.2 ](tm2621105d1_ex10-2.htm)\n[Placement Agency Agreement, dated July 22, 2026](tm2621105d1_ex10-2.htm)\n\n \n \n\n[23.1](tm2621105d1_ex5-1.htm)\n[Consent of Sullivan & Worcester LLP (included in Exhibit 5.1)](tm2621105d1_ex5-1.htm)\n\n \n \n\n[99.1](tm2621105d1_ex99-1.htm)\n[Press release dated July 22, 2026](tm2621105d1_ex99-1.htm)\n\n \n \n\n104\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the\nundersigned hereunto duly authorized.\n\n \n\nDated: July 22, 2026\nDARIOHEALTH CORP.\n\n \n \n\n \nBy:\n/s/ Chen Franco-Yehuda\n\n \n \nName:\nChen Franco-Yehuda\n\n \n \nTitle:\nChief Financial Officer, Treasurer and Secretary"}